Serplulimab: First Approval

Serplulimab (汉斯状 ® ) is an intravenously administered anti-PD-1 antibody being developed by Shanghai Henlius Biotech, Inc. for the treatment of solid tumours. Anti-PD-1 immunotherapies, such as serplulimab, can stimulate immune responses by relieving PD-1-related immunosuppression. Serplulimab recei...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drugs (New York, N.Y.) N.Y.), 2022-07, Vol.82 (10), p.1137-1141
1. Verfasser:	Lee, Arnold
Format:	Artikel
Sprache:	eng
Schlagworte:	AdisInsight Report Anemia Antibodies Binding sites Biological products Blood Cancer therapies Cervical cancer Colorectal cancer Gastric cancer Immune response Immunosuppression Immunotherapy Internal Medicine Intestinal obstruction Kidney diseases Lung cancer Medicine Medicine & Public Health Metastases Metastasis Microsatellite instability Microsatellites Patients PD-1 protein Pharmacokinetics Pharmacology/Toxicology Pharmacotherapy Solid tumors Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!